Approved autism study marks the start of the expansion into the Middle East

SensoDetect, Arabian Trade House (ATH) and Princess Nourah bint Abdulrahman University’s (PNU) Hospital, King Abdullah bin Abdulaziz University Hospital (KAAUH), Riyadh, Kingdom of Saudi Arabia have now agreed upon the terms of the previously announced autism study. The longitudinal study, “Early, objective detection of autism” is planned to start in January 2024 and will mark the start of the next major product launch for SensoDetect and its distributor ATH. A start that ATH projects will result in millions of measurements in the Middle east during the coming years.

About Princess Nourah bint Abdulrahman University’s (PNU) Hospital, King Abdullah bin Abdulaziz University Hospital (KAAUH)

King Abdullah bin Abdulaziz University Hospital is a 406-bedded teaching hospital, accredited by JCIA and CBHAI. Presently there are centers of excellence in women's health, pediatric and adolescent health, including a Child Development Center specializing in autism and attention disorders. The organization has commenced the journey to Magnet recognition, an accreditation awarded to exceptional health care organizations. KAAUH is located on Princess Nourah bint Abdulrahman University campus, which has 20 colleges with 121 academic programs, PNU is a premier academic institution dedicated to graduating exceptional, highly qualified specialists based on international standards. The hospital was officially inaugurated on 28 March 2017. Additionally, the campus hosts an impressive Health Sciences Research Center and the largest Simulation Center in the Middle East.

The Study: Early, objective detection of autism

More information on the study and its prominent team members will be announced in conjunction with the opening ceremony of the Autism study “Early, objective detection of autism” at the Princess Noura University, Riyadh, Saudi Arabia, during January in 2024.

“This study is in line with the Saudi Vision 2030 and an important step in ensuring a comprehensive, effective, and integrated health care with data-driven treatment plans for ASD. The area of ASD is especially important as there is a strong need for detecting ASD as early as possible to ensure the best possible support for children with ASD.” Says the Principal lead investigator of the study from PNU/KAAUH.

About Arabian Trade House

Established in 1978, Arabian Trade House has grown to be a trusted name in the medical distribution sector in Middle East. Their expertise lies in the distribution of medical devices, consumables, pharmaceuticals, and industrial/life science equipment throughout the Kingdom of Saudi Arabia and the broader Gulf region. Central to the company’s operations is their mission: to enhance the health and wellbeing of the GCC and Middle East communities. We provide top-tier healthcare services, training, and education. By keeping aligned with the latest medical standards, ATH aim to provide services that make a difference to stand ready to address the diverse medical needs of the Middle East community.

“Our partnership as the exclusive distributor for several international companies has allowed us to offer a diverse range of products. From state-of-the-art cardiac surgery devices to specialized dental instruments, we ensure that our offerings meet the highest standards of quality and efficiency. Furthermore, ATH has a dedicated team of 500 employees spread across specialized divisions. Our operational base is in Riyadh, but our reach extends much further. With branches in key locations such as Jeddah and Al Khobar in Saudi Arabia and an international footprint in Dubai, U.A.E, we will ensure that the SensoDetects offering will reach a large area to start with. Adding our affiliations with companies in countries like Jordan, Oman, Bahrain, Qatar, and Kuwait we will secure our commitment to make sure that SensoDetects reaches millions of measurements in the region for the years to come.” Says the consulting VP of sales at the Medical department of Arabian Trade House.

CEO comments

”This study is groundbreaking in many ways. For the field of science, it will explore the boundaries for how early it is possible to detect ASD. This is important as intervention support services for ASD should begin as early as possible to help children and their families effectively manage symptoms as early as possible. This as children with ASD who receive early intervention services simply have better learning outcomes, better development of social skills, and are more likely to gain independence. How early we can detect ASD remains to be seen, but the study and the collaboration with PNU, KAAUH and ATH will also spark a widespread interest in the SensoDetect offering in GCC, an offering that may not sell in the millions to start with but could very well in the coming 5 years. The next step is now to finalize the contract negotiations with the hospital and the remaining clinics in Saudi Arabia. I expect a modest start in Saudi Arabia with about 1500 measurements for ASD in 2024 and 6000 in 2025. The big potential, to reach more than 500.000 measurements per year, will start 2026.“ Says CEO Per-Anders (PA) Hedin. 

This disclosure contains information that SensoDetect AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-12-2023 15:05 CET.

För ytterligare information, vänligen kontakta:

PA Hedin, VD Sensodetect AB

+46 (0)73-068 64 20
pa.hedin@sensodetect.com

SensoDetect AB är ett Med Tech AI-företag noterat på Spotlight stock market. Företaget grundades i Lund 2005, baserat på mer än 30 års forskning inom klinisk psyko akustik vid Institutionen för Neurovetenskap vid Lunds universitet. Inledningsvis låg fokus på patienter med schizofreni, då det är en sjukdom där hörselhallucinationer är ett vanligt symtom, men idag erbjuder företaget ett flertal andra tjänster inom produktområdena diagnostik, medicinering och hälsa. Produkterna används inom både privat och offentlig vård som komplement till andra observationer vid ADHD, schizofreni och autismutredningar, vid mätning av läkemedelseffekt samt vid screening av hörsel. SensoDetects unika och globalt patenterade teknik minskar den ekonomiska påverkan på hälso- och sjukvården samt samhället och ger patienter och dess anhöriga ett snabbare och säkrare resultat.

Mer info på https://www.sensodetect.com/